India I Equities

Infrastructure

Company Update

Change in Estimates ☑ Target ☑ Reco ☑

20 November 2021

## **PNC Infratech**

OB needs augmentation; valuation comforting; raising to a Buy

The continuing good pace of execution with no orders since Jan'21 mean PNC's revenue assurance is now ordinary. Citing sound prospect pipeline, and as it expects competition to moderate (with the benefits of diluted PQs/other relaxations announced under the AtmaNirbhar Bharat Scheme set to lapse on 31st Dec'21), management is sanguine of adding orders in time to keep growth going beyond the foreseeable future. The balance sheet is sturdy, and with Ghaziabad-Aligarh monetisation nearing fruition, it has potential to be sturdier. On the proven execution abilities, a well-set BS and the potential, we raise our rating to a Buy with a higher TP of Rs389 (on rolling forward to FY24).

Assurance ordinary. Q2 was devoid of any orders, but the firm OB, on including UP drinking water-supply orders, rose ~Rs11bn q/q to ~Rs132bn. With no orders for over nine months now, and as the pace of execution has held well, revenue assurance is now ordinary (~2.3x); the OB, thus, needs to be attended to at the earliest. Citing a healthy prospect pipeline, aiming to benefit from the general surge in awarding in H2 and expected moderation in competition, management looks to add orders of ~Rs80bn in FY22.

Net cash status held. The q/q lengthened receivables cycle and lower mobilisation advances pulled down the net cash balance  $\sim$ Rs1.3bn q/q to  $\sim$ Rs1.7bn. Nevertheless, the balance sheet is still in shape to deliver growth in the short to medium term. Post-Q2 recoveries of  $\sim$ Rs3bn also augur well.

Asset-monetisation progressing. With change-in-ownership approval secured, the Ghaziabad-Aligarh monetisation is in the final leg of consummation. The two NoCs (COD, de-scoping) remain, and management looks to have them at the earliest. Five hybrid annuities and a BOT-annuity are on the block, and suitors are in the fray. The InvIT option, too, is on the table.

**Valuation.** On a mix of tweaked revenue estimates (to account for the Q2 execution, delayed inflows) and higher margins, earnings are  $\sim$ 2% higher in FY22, but lower  $\sim$ 1% in FY23. On the newly introduced FY24e, the stock is available (excl. investments) at a PER of 11x FY24e. **Risk.** Delayed inflows.

| Key financials (YE Mar) | FY20   | FY21   | FY22e  | FY23e  | FY24e  |
|-------------------------|--------|--------|--------|--------|--------|
| Sales (Rs m)            | 48,779 | 49,254 | 59,511 | 69,640 | 78,705 |
| Net profit (Rs m)       | 4,603  | 3,619  | 4,788  | 5,734  | 6,327  |
| EPS (Rs)                | 17.9   | 14.1   | 18.7   | 22.4   | 24.7   |
| Growth (%)              | 41.7   | -21.4  | 32.3   | 19.8   | 10.3   |
| P/E (x)                 | 5.2    | 18.3   | 16.3   | 13.6   | 12.3   |
| EV / EBITDA (x)         | 2.5    | 9.1    | 9.0    | 7.9    | 7.1    |
| P/BV (x)                | 0.9    | 2.3    | 2.3    | 2.0    | 1.7    |
| RoE (%)                 | 19.7   | 13.3   | 15.2   | 15.7   | 15.0   |
| RoCE (%)                | 28.6   | 21.1   | 21.8   | 21.8   | 20.9   |
| Net debt / equity (x)   | -0.2   | -0.2   | -0.1   | -0.1   | -0.1   |

Rating: **Buy** Target Price: Rs.389 Share Price: Rs.304

| Key data           | PNCL IN / PNCI.BO  |
|--------------------|--------------------|
| 52-week high / low | Rs396 / 157        |
| Sensex / Nifty     | 59636 / 17765      |
| 3-m average volume | \$3.1m             |
| Market cap         | Rs78bn / \$1048.8m |
| Shares outstanding | 257m               |

| Shareholding pattern (%) | Sep-21 | Jun-21 | Mar-21 |
|--------------------------|--------|--------|--------|
| Promoters                | 56.1   | 56.1   | 56.1   |
| - of which, Pledged      | -      | -      | -      |
| Free float               | 43.9   | 43.9   | 43.9   |
| - Foreign institutions   | 11.6   | 9.3    | 10.8   |
| - Domestic institutions  | 28.3   | 29.2   | 27.7   |
| - Public                 | 4.0    | 5.4    | 5.4    |

| Estimates revision (%) | FY22e | FY23e |
|------------------------|-------|-------|
| Sales                  | 0.5   | -1.3  |
| EBITDA                 | 2.1   | -1.1  |
| EPS (Rs)               | 1.7   | -0.9  |



Source: Bloomberg

Prem Khurana Research Analyst

Meet Parikh Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Anand Rathi Research India Equities

# Quick Glance - Financials and Valuations (standalone)


| Fig 1 – Income staten       | Fig 1 – Income statement (Rs m) |         |         |         |         |  |  |  |  |  |  |  |  |
|-----------------------------|---------------------------------|---------|---------|---------|---------|--|--|--|--|--|--|--|--|
| Year-end: Mar               | FY20                            | FY21    | FY22e   | FY23e   | FY24e   |  |  |  |  |  |  |  |  |
| Order backlog               | 86,290                          | 164,515 | 191,527 | 215,087 | 234,516 |  |  |  |  |  |  |  |  |
| Order inflow                | 11,857                          | 127,467 | 86,393  | 93,200  | 98,134  |  |  |  |  |  |  |  |  |
| Net revenues                | 48,779                          | 49,254  | 59,511  | 69,640  | 78,705  |  |  |  |  |  |  |  |  |
| Growth (%)                  | 57.5                            | 1.0     | 20.8    | 17.0    | 13.0    |  |  |  |  |  |  |  |  |
| Direct costs                | 37,819                          | 39,470  | 47,686  | 56,039  | 63,502  |  |  |  |  |  |  |  |  |
| SG&A                        | 3,317                           | 3,057   | 3,591   | 4,170   | 4,690   |  |  |  |  |  |  |  |  |
| EBITDA                      | 7,643                           | 6,728   | 8,234   | 9,431   | 10,512  |  |  |  |  |  |  |  |  |
| EBITDA margins (%)          | 15.7                            | 13.7    | 13.8    | 13.5    | 13.4    |  |  |  |  |  |  |  |  |
| Depreciation                | 1,264                           | 1,124   | 1,329   | 1,475   | 1,667   |  |  |  |  |  |  |  |  |
| Other income                | 885                             | 752     | 654     | 577     | 542     |  |  |  |  |  |  |  |  |
| Interest expenses           | 1,144                           | 771     | 863     | 870     | 931     |  |  |  |  |  |  |  |  |
| PBT                         | 6,120                           | 5,585   | 6,696   | 7,663   | 8,455   |  |  |  |  |  |  |  |  |
| Effective tax rate (%)      | 24.8                            | 35.2    | 28.5    | 25.2    | 25.2    |  |  |  |  |  |  |  |  |
| + Associates / (Minorities) | -                               | -       | -       | -       | -       |  |  |  |  |  |  |  |  |
| Net income                  | 4,603                           | 3,619   | 4,788   | 5,734   | 6,327   |  |  |  |  |  |  |  |  |
| Adjusted income             | 4,603                           | 3,619   | 4,788   | 5,734   | 6,327   |  |  |  |  |  |  |  |  |
| WANS                        | 257                             | 257     | 257     | 257     | 257     |  |  |  |  |  |  |  |  |
| FDEPS (Rs / sh)             | 17.9                            | 14.1    | 18.7    | 22.4    | 24.7    |  |  |  |  |  |  |  |  |

| Fig 3 - Cash-flow statem          | ent (Rs | m)    |        |        |        |
|-----------------------------------|---------|-------|--------|--------|--------|
| Year-end: Mar                     | FY20    | FY21  | FY22e  | FY23e  | FY24e  |
| PBT + Net interest expense        | 6,379   | 5,604 | 6,904  | 7,956  | 8,845  |
| + Non-cash items                  | 1,264   | 1,124 | 1,329  | 1,475  | 1,667  |
| Oper. prof. before WC             | 7,643   | 6,728 | 8,234  | 9,431  | 10,512 |
| - Incr. / (decr.) in WC           | -1,303  | 3,227 | 2,263  | 2,904  | 1,932  |
| Others incl. taxes                | 1,612   | 1,998 | 1,908  | 1,929  | 2,128  |
| Operating cash-flow               | 7,335   | 1,503 | 4,062  | 4,599  | 6,452  |
| - Capex (tang. + intang.)         | 927     | 1,835 | 1,063  | 1,663  | 1,875  |
| Free cash-flow                    | 6,408   | -332  | 2,999  | 2,937  | 4,577  |
| Acquisitions                      | -       | -     | -      | -      | -      |
| - Div.(incl. buyback & taxes)     | 309     | -     | 128    | 257    | 257    |
| + Equity raised                   | -       | -     | -      | -      | -      |
| + Debt raised                     | -23     | 1,716 | -1,048 | -252   | 364    |
| - Fin investments                 | 1,625   | 1,115 | 2,495  | 3,190  | 3,500  |
| - Net interest expense + misc.    | 145     | -13   | 208    | 293    | 390    |
| Net cash-flow                     | 4,306   | 282   | -880   | -1,055 | 795    |
| Source: Company, Anand Rathi Rese | earch   |       |        |        |        |

| Fig         | 5 -    | - P  | ric     | e n    | nov    | /er    | nei    | nt     |        |        |        |        |        |        |        |        |        |        |        |        |        |
|-------------|--------|------|---------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| (Rs)<br>450 |        |      |         |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| 400         |        |      |         |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| 350         |        |      |         |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        | 1      |
| 300         |        |      |         |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        | N      | _]     |
| 250         |        |      |         |        |        |        |        |        |        |        |        |        |        |        |        |        |        | Λ      | W      |        |        |
| 200         |        |      |         |        | M      | ٨.     | A      |        |        |        | 1      | W      | 1./    | -      |        |        | _      | ٦      |        |        |        |
| 150         |        |      | N       | w      | )      |        | VVI    | WY     | L۸     | N      | W.     |        | -      | }      | 4.4    | W      |        |        |        |        |        |
| 100         | >      | -    | <b></b> |        |        |        |        |        |        |        |        |        |        |        | W      |        |        |        |        |        |        |
| 50          |        |      |         |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |
| 0           | Nov-16 |      |         | Aug-17 | Nov-17 | Feb-18 | May-18 | Aug-18 | Nov-18 | Feb-19 | May-19 | Ang-19 | Nov-19 | Feb-20 | May-20 | Aug-20 | Nov-20 | Feb-21 | May-21 | Aug-21 | Nov-21 |
| Sourc       | ce: i  | Bloo | mbe     | erg    |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |        |

| Fig 2 – Balance sheet (Rs m) |        |        |        |        |        |  |  |  |  |  |  |  |
|------------------------------|--------|--------|--------|--------|--------|--|--|--|--|--|--|--|
| Year-end: Mar                | FY20   | FY21   | FY22e  | FY23e  | FY24e  |  |  |  |  |  |  |  |
| Share capital                | 513    | 513    | 513    | 513    | 513    |  |  |  |  |  |  |  |
| Net worth                    | 25,466 | 29,085 | 33,744 | 39,222 | 45,293 |  |  |  |  |  |  |  |
| Debt                         | 3,266  | 3,992  | 2,945  | 2,693  | 3,057  |  |  |  |  |  |  |  |
| Minority interest            | -      | -      | -      | -      | -      |  |  |  |  |  |  |  |
| DTL / (Assets)               | -1,215 | -225   | -225   | -225   | -225   |  |  |  |  |  |  |  |
| Capital employed             | 27,517 | 32,852 | 36,464 | 41,690 | 48,124 |  |  |  |  |  |  |  |
| Net tangible assets          | 5,865  | 6,535  | 6,311  | 6,500  | 6,711  |  |  |  |  |  |  |  |
| Net intangible assets        | 16     | 22     | 14     | 12     | 10     |  |  |  |  |  |  |  |
| Goodwill                     | -      | -      | -      | -      | -      |  |  |  |  |  |  |  |
| CWIP (tang. & intang.)       | -      | 34     | -      | -      | -      |  |  |  |  |  |  |  |
| Investments (strategic)      | 6,732  | 7,465  | 10,965 | 14,155 | 17,655 |  |  |  |  |  |  |  |
| Investments (financial)      | 623    | 1,005  | -      | -      | -      |  |  |  |  |  |  |  |
| Current assets (ex cash)     | 22,252 | 25,600 | 31,947 | 37,637 | 42,030 |  |  |  |  |  |  |  |
| Cash                         | 7,401  | 7,683  | 6,802  | 5,748  | 6,542  |  |  |  |  |  |  |  |
| Current liabilities          | 15,371 | 15,492 | 19,576 | 22,363 | 24,823 |  |  |  |  |  |  |  |
| Working capital              | 6,881  | 10,108 | 12,371 | 15,275 | 17,207 |  |  |  |  |  |  |  |
| Capital deployed             | 27,517 | 32,852 | 36,464 | 41,690 | 48,124 |  |  |  |  |  |  |  |
| Contingent liabilities       | 27,283 | 24,153 | -      | -      | -      |  |  |  |  |  |  |  |

| Fig 4 – Ratio analysis             |       |      |       |       |       |
|------------------------------------|-------|------|-------|-------|-------|
| Year-end: Mar                      | FY20  | FY21 | FY22e | FY23e | FY24e |
| P/E (x)                            | 5.2   | 18.3 | 16.3  | 13.6  | 12.3  |
| EV / EBITDA (x)                    | 2.5   | 9.1  | 9.0   | 7.9   | 7.1   |
| EV / Sales (x)                     | 0.4   | 1.2  | 1.2   | 1.1   | 0.9   |
| P/B (x)                            | 0.9   | 2.3  | 2.3   | 2.0   | 1.7   |
| RoE (%)                            | 19.7  | 13.3 | 15.2  | 15.7  | 15.0  |
| RoCE (%)                           | 28.6  | 21.1 | 21.8  | 21.8  | 20.9  |
| RoIC (%)                           | 27.1  | 18.2 | 19.7  | 19.5  | 18.1  |
| DPS (Rs / sh)                      | 1.0   | -    | 0.4   | 0.8   | 0.8   |
| Dividend yield (%)                 | 0.3   | -    | 0.1   | 0.3   | 0.3   |
| Dividend payout (%) - incl. DDT    | 6.7   | -    | 2.7   | 4.5   | 4.1   |
| Net debt / equity (x)              | -0.2  | -0.2 | -0.1  | -0.1  | -0.1  |
| Receivables (days)                 | 60    | 62   | 70    | 75    | 75    |
| Inventory (days)                   | 20    | 26   | 31    | 31    | 31    |
| Payables (days)                    | 35    | 53   | 46    | 46    | 46    |
| CFO: PAT%                          | 159.4 | 41.5 | 84.8  | 80.2  | 102.0 |
| Source: Company, Anand Rathi Resea | rch   |      |       |       |       |



## Results, Concall highlights

- Inspiring pace of execution. Q2 revenue from operations were ~53% higher y/y, ~29% q/q, to ~Rs16.2bn. Though a part of the growth could be attributed to the Covid first-wave-impacted base from Q2 FY21, and the second-wave disrupted Q1 FY22, the performance is still inspiring.
  - The healthy pace of execution in general, and at Mumbai-Nagpur as well as Aligarh-Kanpur–V in particular, hold the key to the inspiring Q2 revenue from operations. The two Puravanchal Expressway packages and Nagina-Kashipur also appear to be among the top-five contributors.
  - The continuing healthy pace of execution at its road OB and the gradual commencement of construction/stabilising pace of execution at the non-road OB would bolster the performance.
  - Notwithstanding the strong Q2, management, talking of the protracted monsoon-impacted Q3 pace of execution, mostly retained its FY22 revenue guidance at 20-25%.
- EBITDA margin holds the fort. The ~13.7% margin was ~23bps better y/y, and q/q contracted only ~30bps. The Q1 margin performance was largely boosted by the gross margin, aided by a favourable project mix and the effectively managed commodity price pressures (helped by escalation clauses).
  - Management highlights that its entire OB has pricevariation/escalation clauses in place, and thus it does not see any meaningful variability in its margin performance.
  - Ahead, it expects margins of 13.5-13.75%, slightly lowered from the earlier guided-to 13.5-14%.

| Fig 7 – Financial highlights |         |         |         |         |         |         |       |        |
|------------------------------|---------|---------|---------|---------|---------|---------|-------|--------|
| (Rs m)                       | Q1 FY21 | Q2 FY21 | Q3 FY21 | Q4 FY21 | Q1 FY22 | Q2 FY22 | % Y/Y | % O/O  |
| Revenue from operations      | 9,053   | 10,535  | 13,224  | 16,443  | 12,512  | 16,150  | 53.3  | 29.1   |
| EBITDA                       | 1,198   | 1,421   | 1,785   | 2,324   | 1,754   | 2,216   | 56.0  | 26.3   |
| EBITDA margins (%)           | 13.2    | 13.5    | 13.5    | 14.1    | 14.0    | 13.7    | 23bps | -30bps |
| Interest                     | 253     | 218     | 153     | 148     | 180     | 243     | 11.5  | 34.7   |
| Depreciation                 | 270     | 272     | 282     | 300     | 315     | 328     | 20.5  | 4.1    |
| Other income                 | 191     | 148     | 243     | 171     | 178     | 174     | 17.7  | -1.9   |
| PBT                          | 866     | 1,079   | 1,594   | 2,047   | 1,437   | 1,820   | 68.7  | 26.6   |
| Tax                          | 265     | 386     | 562     | 753     | 504     | 466     | 20.7  | -7.5   |
| PAT                          | 601     | 693     | 1,032   | 1,294   | 933     | 1,354   | 95.4  | 45.1   |
| EPS (Rs)                     | 2.3     | 2.7     | 4.0     | 5.0     | 3.6     | 5.3     | 95.4  | 45.1   |
| Source: Company              |         |         |         |         |         |         |       |        |

- Strong earnings performance. The strong, ~56% y/y, growth in absolute EBITDA helped Q2 earnings rise ~95% y/y to ~Rs1.4bn. Sequentially, earnings rose ~45%, largely aided by the ~26% higher operating profitability.
  - Besides operating profitability, earnings growth was also boosted by the capped rise in depreciation (true y/y and q/q; on contained capex) and in finance costs (true y/y). The lower effective tax rate (true y/y and q/q) too was responsible for the inspiring earnings growth.

### **BOT** operations

- The Q2 FY22 gross toll collection was up ~5% y/y, ~4% q/q, to ~Rs2.05bn on the mostly-receded impact of the Covid'19 (first and second waves).
  - Though collections at two of its five BOT-toll assets grew in double digits y/y, the blended growth was largely dictated by the two largest contributors, Kanpur-Ayodhya and Ghaziabad-Aligarh.
  - Generally a weak quarter sequentially (owing to the monsoon), Q2 FY22 contrasted favourably with Q1 FY22, which was Covid'19 second-wave impacted.

Fig 8 - BOT toll income\* (Rs m) Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 Q2 FY22 % Y/Y % Q/Q Gwalior-Bhind 83 129 133 134 106 115 -11.1 8.5 Kanpur-Ayodhya 723 1,020 1,241 1,140 1,010 1,050 2.9 4.0 Kanpur-Kabrai 196 173 250 296 240 220 27.2 -8.3 Bareily-Almora 78 107 140 135 109 123 14.8 12.8 Ghaziabad-Aligarh 276 513 629 594 503 537 4.7 6.8 1,356 Total 1,943 2,393 2,299 1,968 2,045 5.3 3.9 Source: Company \* Excluding two operational BOT-Annuity assets and operational hybrid annuity

■ Notwithstanding the y/y and q/q higher gross toll collection, and more operational hybrid annuities, the reported ~Rs2bn BOT-toll/annuity revenue was down ~7% y/y, ~3% q/q. This, we believe, would have been due to lower revenue under the service-concession agreements from the under-construction hybrid annuities. The segment margin, at ~50%, contracted ~744bps y/y, ~636bps q/q.


| Fig 9 – Consolidated finar | ncials – Segment | highlights |         |         |         |         |       |       |
|----------------------------|------------------|------------|---------|---------|---------|---------|-------|-------|
| (Rs m)                     | Q1 FY21          | Q2 FY21    | Q3 FY21 | Q4 FY21 | Q1 FY22 | Q2 FY22 | % Y/Y | % Q/Q |
| Segment revenues           |                  |            |         |         |         |         |       |       |
| Contract                   | 9,053            | 10,288     | 13,200  | 16,141  | 12,525  | 15,940  | 54.9  | 27.3  |
| Toll / Annuity             | 1,875            | 2,197      | 2,550   | 2,502   | 2,100   | 2,037   | -7.3  | -3.0  |
| Total                      | 10,928           | 12,485     | 15,749  | 18,643  | 14,625  | 17,977  | 44.0  | 22.9  |
| Segment margins (%)        |                  |            |         |         |         |         |       |       |
| Contract                   | 10.2             | 8.3        | 11.5    | 10.7    | 11.6    | 10.5    | -     | -     |
| Toll / Annuity             | 63.7             | 57.7       | 57.7    | 63.7    | 56.6    | 50.2    | -     | -     |
| Blended                    | 22.2             | 18.8       | 21.2    | 19.0    | 19.6    | 16.5    | -     | -     |
| Source: Company            |                  |            |         |         |         |         |       |       |


The reported BOT-toll/annuity segment includes financials for the two annuity assets, three BOT-toll, one OMT and four operational hybrid annuity assets, but excludes the minority-owned Ghaziabad-Aligarh. Financials also include revenues booked under serviceconcession agreements for the under-construction hybrid annuties.

### Inflows / order backlog

■ Keener competition owing to diluted qualifications, bid security and other norms (under the AtmaNirbhar Bharat Scheme) meant the company missed out on orders for the second straight quarter. Nevertheless, drinking water-supply orders were included in the OB during the quarter.

- On the inclusion of the EPC potential from the drinking water-supply orders in Uttar Pradesh, the end-Q2 FY22 firm OB was up ~Rs10.8bn sequentially (net of the quarter's execution) to ~Rs131.8bn. This implied a book-to-bill of ~2.3x TTM construction revenues, the same as a quarter ago.
  - The end-Q2 OB is good to deliver in the immediate future, but the company would need more at the earliest to sustain the growth beyond the foreseeable future.
  - The end-Q2 OB is still not moving entirely as ~Rs34bn (JV projects; PNC's share at 95%) of drinking water-supply orders in Uttar Pradesh have yet to start contributing, and work at an irrigation order (of ~Rs10bn) in Andhra Pradesh has been temporarily halted.
  - Management expects the AP irrigation order to start moving in Jan'22, and ~Rs10bn of the UP drinking-water-supply orders to turn contributing by end-FY22.





- Buoyed by the healthy bid prospects and the government's continued focus on infrastructure spending to boost the overall economy, and as the qualification norms and other bid conditions revert to normal (likely by Dec'21), management expects to add orders in time to keep growth going. Its focus would be firmly on the roads sector for the foreseeable future. It expects to add orders in the airports sector as well.
- Given this, it targets FY22 order additions at ~Rs80bn. It expects a fair mix of EPC and hybrid annuities (50:50). It expects the airports segment to comprise ~10% of the targeted additions. For this, its eyes are set on road and highway projects, mainly from the NHAI.
  - To this effect, it has its mind on immediate opportunities of ~Rs92bn. It highlights, this is a 70:30 split between hybrid annuities and EPC.
  - Besides, it has identified NHAI projects of ~Rs250bn on offer.
     These are likely to come up for bidding in another 2-3 months.
  - It is evaluating a number of state opportunities, and many states are coming up with expressways, but bids for them have yet to be floated.
  - On the Ganga Expressway in Uttar Pradesh, management is not yet clear regarding bidding. Earlier, it said the decision to bid for the


- project would be taken based on the final modalities. The bid dates for this project have yet again been extended.
- In drinking water-supply, management is keenly viewing some opportunities in Uttar Pradesh, but the final decision to bid or not is not yet firm. We believe the decision to bid for any further opportunities in this segment would take note of the progress at the current set of irrigation and water-supply orders. The present share of irrigation and water-supply orders is pegged at ~28%, and management intends to maintain the share at 20-25% in FY23 and FY24.


## Update on hybrid annuity projects

- Of PNC's hybrid annuity portfolio of eleven projects, it has received COD for one and PCOD for three; the other seven are at various stages of construction. Of these eleven, discussions can take place under two broad heads:
  - **Completed projects.** With PCOD for three in Jun'21, four from the portfolio of eleven are now operational, and have turned yielding.
  - Under-construction projects. Of the seven hybrid annuity projects being constructed, the Jhansi-Khajuraho Package-II and Chakeri-Allahbad are already at advanced stages. The other five received appointed dates of from Jan'21 to May'21, and work is going well. Unnao-Lalganj, with 19<sup>th</sup> May'21 as the appointed date, was the last to be appointed.
- With four of the eleven assets already operational, and two more due to turn contributing sooner than later, a gradual commissioning renders these assets lucrative to prospective buyers. Thus, monetisation efforts have already started gaining pace.
- The equity required for all the eleven hybrid annuity assets is pegged at ~Rs14.68bn.
  - For its older seven hybrid annuities, SPVs require equity of ~Rs8.48bn. Of this, the company has infused ~Rs6.3bn, incl. ~Rs0.42bn in Q2 (~Rs0.65bn in H1).
  - The equity infusion required for the newer four assets are ~Rs6.2bn. Of this, the company has cumulatively infused ~Rs0.35bn (no infusion in H1).
- Of the balance estimated ~Rs8bn, it looks to infuse~Rs2.8bn during the rest of FY22 and ~Rs3.2bn in FY23, with the balance thereafter. This is subject to the progress in construction.

## Balance sheet

- A q/q lengthened receivables cycle, lower mobilisation advances and the decision to support its vendors pulled down the net cash balance ~Rs1.3bn q/q to ~Rs1.7bn. Nevertheless, the balance sheet is still in shape to deliver growth in the short to medium term.
  - During the quarter, the receivables cycle was five days longer, at 81. This is the single largest contributor to the lower net cash balance. Management highlights that this is partly explained by the deliberately delayed drawdown of SPV level debt, and utilisation of standalone cash & equivalents to fund the construction (to improve IRR).





- During the quarter, the receivables cycle was five days longer, at 81. This is the single largest contributor to the lower net cash balance. Management highlights that this is partly explained by the deliberately delayed drawdown of SPV level debt, and utilisation of standalone cash & equivalents to fund the construction (to improve IRR).
- Mobilisation advances were down ~Rs0.9bn q/q to ~Rs4.95bn (on account of settlements against bills raised), and of payables (notwithstanding the greater scale) being down ~Rs133m to ~Rs5.2bn.
- The standalone gross debt was down ~Rs0.6bn q/q to ~Rs3.35bn. But the decline in cash & equivalents was steeper at ~Rs1.98bn q/q, to ~Rs5.1bn, as management decided to utilise book-cash to fund project execution.
- The end-Sep'21 gross debt was entirely for equipment finance. There were no loans for working capital
- Notwithstanding the q/q lengthened receivables cycle, the favourable movement in some of the other key constituents of the working capital helped to a q/q flat overall working-capital cycle (at 103 days at 30<sup>th</sup> Sep'21).
  - Subsequent to the quarter, however, the working-capital cycle has been pruned, as ~Rs3bn of trade receivables were realised in Oct'21 (originally due in Sep'21).
- On 30th Sep'21, debt at SPVs (incl. Ghaziabad-Aligarh, ineligible for consolidation) was ~Rs47.3bn, a ~Rs0.9bn net rise q/q on the fresh draw-downs by the SPVs for hybrid annuities (to carry out construction), but partly restricted on repayments by operational BOT-toll/annuity SPVs.
  - Debt for its operational BOT-toll/annuity assets contracted ~Rs1.1bn q/q to ~Rs17.1bn, though for its hybrid annuity assets with COD/PCOD rose ~Rs1.6bn q/q (drawdowns upon COD, net of repayments) to ~Rs19.5bn. The debt for the hybrid annuities being constructed rose ~Rs0.45bn q/q to ~Rs10.65bn.

### Guidance

■ Though no orders have been bagged this financial year (to date), management retained its FY22 order-addition guidance of ~Rs80bn. The

- already placed bids and a healthy prospect pipeline keep it sanguine about its targeted additions. Management expects airports to account for  $\sim 10\%$  of the targeted additions, and to evaluate water-supply/irrigation orders based on the progress at the existing set of orders.
- With the strong Q2, revenue growth was slightly firmed up from the earlier guidance of ~20%, to 20-25%. The guidance takes into account the prolonged monsoon, and its impact on the Q3 FY22 pace of execution.
- On the core construction EBITDA margins, management maintained its guidance of ~13.5–13.75%. On the recent commodity price rise cutting into margins, it said that all its projects have escalation clauses in place, which would help alleviate the pressure.
- The FY22 capex guidance too was mostly retained, at Rs1bn-1.2bn. Of this, the company has incurred capex of ~Rs0.15bn in H1.

## Other highlights

- Ghaziabad-Aligarh monetisation. With the recent receipt of approval for change-in-ownership and lenders NoCs received earlier, the company is a step closer to close this transaction with Cube Highways. The pending NoCs include approvals for COD and de-scoping, and these two would pave the way for it to transfer the asset, and realise monies. Though the efforts seem to be reaching fruition, management is still silent on the envisaged equity consideration. This is because the equity consideration would depend on settlement of claims for revenue shortfalls, as well as certain other conditions.
  - Though two NOCs remain, management hopes of consummation in FY22 itself.
  - With it hopeful of realising claims from the NHAI toward the revenue loss in this project, management does not see any writedowns to the exposure.
- Asset monetisation efforts for other assets. Monetisation efforts are under way for other assets as well (BOT-Annuity and operational hybrid annuity projects), and have been making gradual progress.
  - Management said it has received offers from a couple of prospective buyers for projects with ~Rs6.8bn equity infused. These include five hybrid annuities and an operational BOT-annuity asset.
  - Though the offers are already in place for these five, management highlights that the InvIT option too is being considered for the five on the block now, and the future assets.
- Status on drinking water-supply, irrigation orders. Currently, only a drinking water-supply order in Uttar Pradesh is moving. Management expects others to turn contributing shortly. The status is as follows:
  - Of the Uttar Pradesh drinking water-supply orders of ~Rs37bn (PNC's share: ~95% of the total), work is gradually progressing at the smallest one of ~Rs2.9bn (125 villages). On the two larger jobs comprising 3,427 villages, work has yet to begin. Tripartite agreements for the 233 DPRs/villages with EPC potential of ~Rs4bn have already been completed, and DPRs are at various stages for the balance. Management expects the orders of ~Rs10bn to be under execution by the year end. It does not see the ensuing

- UP state elections to have any bearing as these are critical projects with joint funding from the state and Centre.
- Though it had commenced work at its ~Rs10bn irrigation order in Andhra Pradesh, work is currently on hold due to release of water from the Srisailam reservoir into the canal system. Management says the state government remains committed to the project with efforts underway to garner funds or provide budgetary allocation to complete this project before the 2024 assembly elections. Management expects the work to resume in Jan'22.
- Uttar Pradesh water-supply opportunity. In phase-I, the government earlier gave out works of ~Rs10bn, mostly in dry regions. In phase-II, which is underway with 34,000 villages, the potential is estimated at ~Rs50bn. Management sees the government to come out with works of another ~30,000 villages in phase-III, and the balance works would be carried out in phase-IV. Management pegs the cumulative opportunity spread over 98,000 villages and 62,000 gram sabhas at ~Rs1trn.
- Keener competition in bidding for projects. Management said that on account of lower PQ requirements by MoRTH and NHAI, and as other conditions were relaxed, competition has intensified. However, with the PQ requirement likely to be restored (likely to last up to Dec'21), and as other conditions return to the pre-Covid levels, management expects competition to ease.
- Early-completion bonuses. Four months ahead of the scheduled completion, the Puravanchal package-V becomes eligible for an early-completion bonus. Management expects it to be recognised in Q4 FY22 (post-completion of some processes). Mumbai-Nagpur too would be eligible for an early-completion bonus, but this is unlikely before Q1 FY23. The early completion bonus for the Aligarh-Moradabad is expected by end-FY22.

## Earnings revision, Valuation

Our revenue estimates take into account the stronger-than-anticipated Q2 and the longer-than-expected wait for new orders. Consequently, FY22e revenue is ~0.5% higher, while FY23e is down ~1.3%. Margin estimates, though, have been firmed up to reflect the H1 performance, and consequently the ability to deal with input price pressures. FY22e earnings, are, thus, ~2% higher, but ~1% lower for FY23e.

We introduce FY24e with ~Rs78.7bn revenue, ~Rs10.5bn EBITDA, ~Rs6.3bn net profit. This contrasts well with FY23's ~Rs69.6bn, ~Rs9.4bn and ~Rs5.7bn.

We roll forward our valuation to FY24e. We value the core construction business at a 13x PE multiple for FY24 (lowered from 14x FY23e). The exposure to asset-ownership has been valued using a mix of DCF and an equity-invested approach for hybrid annuities. Resultantly, the construction business is valued at Rs321 a share (up from Rs304) and asset ownership at Rs68 (up from Rs55 earlier). The per-share target price works out to Rs389 (up from Rs360 earlier).

| Fig 14 - Estim      | ates revision |        |               |        |            |      |  |
|---------------------|---------------|--------|---------------|--------|------------|------|--|
| (Rs m)              | Old estima    | tes    | Revised estir | nates  | Change (%) |      |  |
|                     | FY22          | FY23   | FY22          | FY23   | FY22       | FY23 |  |
| Revenue             | 59,196        | 70,532 | 59,511        | 69,640 | 0.5        | -1.3 |  |
| EBITDA              | 8,067         | 9,536  | 8,234         | 9,431  | 2.1        | -1.1 |  |
| EPS (Rs)            | 18.3          | 22.5   | 18.7          | 22.4   | 1.7        | -0.9 |  |
| Source: Anand Rathi | Research      |        |               |        |            |      |  |

At the ruling price, the stock (excl. investments) quotes at PERs of 14.4x FY22e, 12x FY23e and 10.9x FY24e. On P/BV, it trades at 2.3x FY22e, 2x FY23e and 1.7x FY24e, against our target-price-implied exit P/BV of 2.2x FY24e.



Source: Bloomberg, Anand Rathi Research

## Risks

- Significant delay in orders won
- Failure to exercise financial prudence.

### **Appendix**

### **Analyst Certification**

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies Rating and Target Price History (as of 20 November 2021)



### **Anand Rathi Ratings Definitions**

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

| •  |      |       |      |  |
|--|------|-------|------|--|
| Ratings Guide (12 months)  |      |       |      |  |
|  | Buy  | Hold  | Sell |  |
| Large Caps (>US\$1bn)  | >15% | 5-15% | <5%  |  |
| Mid/Small Caps ( <us\$1bn)< td=""><td>&gt;25%</td><td>5-25%</td><td>&lt;5%</td><td></td></us\$1bn)<> | >25% | 5-25% | <5%  |  |

### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity) is a subsidiary of Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX) and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged in the business of Stock Broking, Depository Participant and Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

### Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

### Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

| Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.   | No |
|---|----|
| ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report? | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company  | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?   | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months   | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months  | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months  | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months        | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report   | No |
| ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.   | No |

### Other Disclosures pertaining to distribution of research in the United States of America

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer, Cabrera Capital Markets. ("Cabrera"). Transactions in securities discussed in this research report should be effected through Cabrera or another U.S. registered broker dealer.

- 1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
- 2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
- 5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
- 6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
- © 2021. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.

Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.